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STAT3 modulates β-cell cycling in injured mouse
pancreas and protects against DNA damage
S De Groef1, D Renmans1, Y Cai1, G Leuckx1, S Roels1, W Staels1,2,3, G Gradwohl4, L Baeyens1,5, Y Heremans1, GA Martens1,6,
N De Leu1,7,8, M Sojoodi1, M Van de Casteele1,9 and H Heimberg*,1,9
Partial pancreatic duct ligation (PDL) of mouse pancreas induces a doubling of the β-cell mass mainly through proliferation of pre-
existing and newly formed β-cells. The molecular mechanism governing this process is still largely unknown. Given the
inflammatory nature of PDL and inflammation-induced signaling via the signal transducer and activator of transcription 3 (STAT3),
the activation and the role of STAT3 in PDL-induced β-cell proliferation were investigated. Duct ligation stimulates the expression
of several cytokines that can act as ligands inducing STAT3 signaling and phosphorylation in β-cells. β-Cell cycling increased by
conditional β-cell-specific Stat3 knockout and decreased by STAT3 activation through administration of interleukin-6. In addition,
the level of DNA damage in β-cells of PDL pancreas increased after deletion of Stat3. These data indicate a role for STAT3 in
maintaining a steady state in the β-cell, by modulating its cell cycle and protection from DNA damage.
Cell Death and Disease (2016) 7, e2272; doi:10.1038/cddis.2016.171; published online 23 June 2016
Signal transducers and activators of transcription (STAT)
proteins are SH2 domain-containing cytoplasmic transcription
factors expressed by various cell types. On receptor binding,
specific cytokines, growth factors and hormones induce
tyrosine phosphorylation, dimerization and activation of STAT
proteins.1 Although discrete phenotypes have been described
after ablation of most Stat genes, Stat3 knockout results in
early embryonic lethality.2 This ubiquitously expressed tran-
scription factor is activated by a large number of ligands,
including all members of the interleukin 6 (IL6) cytokine family.
Among other factors that activate STAT3 in a cell-dependent
manner are the IL10 cytokine family, interferons (IFNs), leptin,
prolactin, epidermal growth factor (EGF), vascular endo-
thelial growth factor (VEGF), Hepatocyte growth factor (HGF),
platelet-derived growth factor (PDGF) and colony-stimulating
factors (CSFs).2,3 Tissue-specific conditional knockout of
Stat3 identified a role for STAT3 in cell migration,4–6 cell
proliferation,7 (anti/pro)apoptotic signaling,7,8 expression of
acute-phase response genes,9 anti-inflammatory10 and
neurotrophic signaling.11
In Stat3lox/lox mice that express Cre recombinase under the
control of the Pdx1 promoter,12,13 some studies excluded a
role for STAT3 in the development and function of the
pancreatic β-cells,13 whereas others observed glucose intol-
erance and impaired insulin secretion as a result of reduced
VEGF-A signaling and abnormal islet vascularization.12,14
Stat3lox/lox mice with insulin promotor-driven Cre recombinase
are glucose intolerant.15,16 Although these studies suggest a
contribution for STAT3 in β-cell function,16 its role in β-cell
proliferation and survival is unknown. Mature β-cells mainly
renew by self-replication17,18 and their replication potential is
homogenous and delayed by a postmitotic quiescence period
under normal physiological conditions and following minor
injury.19,20 We have previously shown that severe pancreatic
injury impacted by partial pancreatic duct ligation (PDL) leads
to a doubling in β-cell mass21 that mainly results from
proliferation of β-cells, prone to re-divide without refractory
period.22 This process occurs distal to the ligation of the main
pancreatic duct, suggesting autocrine or paracrine regulation,
likely induced by the inflammatory environment of PDL that is
characterized by expression of transforming growth factor-α,
gastrin, IL1a, IL1b, IL6, IL10, IFN-γ and tumor necrosis
factor.23–25 However, this list of factors is likely incomplete
and their role in PDL-induced β-cell proliferation remains to be
determined. Growth factors such as those of the IGF and EGF
family, lactogens, hepatocyte growth factor (HGF), glucagon-
like peptide-1 and parathyroid hormone-related protein stimu-
late rodent β-cell proliferation and survival in vitro and
in vivo.26–28 In addition, cytokines, including members of the
IL6 family, IL10 and IL27, regulate β-cell survival.26–33 As
some of these factors are able to activate STAT3, a role for
STAT3 in β-cell mass maintenance can be envisioned.
We report activation of STAT3 in β-cells of PDL pancreas
and identified factors that are potential activators of the
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JAK2/STAT3 pathway. In PDL pancreas, STAT3modulates the
β-cell cycle and protects β-cells from DNA damage.
Results
PDL-induced injury activates STAT3 in β-cells. Eight
weeks old BALB/cJRj mice underwent PDL or sham surgery
and the expression of Stat3 transcript and protein was
evaluated at day (D) 7 and 14 post surgery. STAT3 protein
was detected in islets in the tail of ligated pancreas (PDL tail),
in the tail of sham pancreas (Sham tail) and in the non-ligated
head of PDL pancreas (PDL head) (Supplementary
Figure S1a). To study STAT3 activation, the expression of
phosphorylated STAT3Y705 (from hereon called P-STAT3)
was examined using a P-STAT3Y705-specific antibody. Sig-
nificantly more P-STAT3+ nuclei were identified among INS+
β-cells of PDL tail at D7 and D14 following surgery, as
compared with PDL head or Sham tail (n= 3; P≤0.005)
(Figures 1a and b). P-STAT3+ nuclei were also observed
among glucagon (GCG)+ α-cells (Supplementary Figure S1b
and Cai et al.34) and among keratin (KRT)19+ duct cells
Figure 1 STAT3 expression and activity are stimulated in β-cells of PDL pancreas. (a) Immunostaining for phospho-STAT3 (Y705) (P-STAT3) and insulin in Sham tail, PDL
head and PDL tail. (b) Quantification of data in a: percentage of P-STAT3+ INS+ cells at day 7 and 14 (D7 and D14) postsurgery (mean± S.E.M., n= 3, ***Po0.001, ns: P40.05,
two-way ANOVA). (c) Stat3 mRNA in β-cells isolated at D7 from the tail of Sham- and PDL pancreas of MIP-RFP mice. Data are expressed as fold change versus Sham (= 1)
(n= 3, #Po0.0001, Sham tail versus PDL tail by unpaired two-tailed t-test). (d) STAT3-activating factors whose expression increased 10-fold or more in PDL pancreas. Data
represent the fold change in expression of each factor in PDL tail as compared with its expression in Sham tail (1) (D3: n= 4, D7: n= 4, D14: n= 3, *Po0.05, **Po0.005,
***Po0.001, #Po0.0001, ns: P40.05, Sham tail versus PDL tail by unpaired two-tailed t-test)
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(Supplementary Figure S1c) of PDL tail. Although the abun-
dance of Stat3mRNA in total PDL tail pancreas was similar to
Sham tail and PDL head pancreas(data not shown), β-cells
isolated from MIP-mRFP D7 PDL tail pancreas contained
twice as much Stat3 transcript compared with β-cells isolated
from Sham tail pancreas (Figure 1c), suggesting β-cell-
specific increase of Stat3 gene expression.
PDL stimulates the expression of STAT3-activating
cytokines and growth factors. Next, the nature of PDL-
induced STAT3 activators was investigated. PDL is char-
acterized by acinar cell loss and formation of neoplastic
ducts, accompanied by a local influx of inflammatory CD45+
cells.21 The cytokine profile of PDL pancreas has been
partially characterized.24,25 A literature search revealed 35
potential activators of STAT3 (Table 1) and their mRNA
abundance was investigated under our experimental condi-
tions. The expression of 12 of these factors increased
more than 10-fold in PDL versus sham tail (Figure 1d).
Among these, IL6 was most strongly induced (488-fold
increase), whereas transcript levels of Clcf1, Csf1, Csf2,
Csf3, Ifng, IL10, IL27, Lep, Lif, Hgf and Osm also increased
(Figure 1d). Cytokines with moderately increased transcript
level (between 1- and 10-fold) included Igf1, IL2, IL7, IL11,
IL15, IL19, Cntf and Pdgfb (Supplementary Figure S2a). The
expression of three factors (Ctf1, Egf and Vegfa) remained
either unchanged or decreased in PDL versus Sham
tail (Supplementary Figure S2b). Finally, a group of nine
cytokines known to activate STAT3, including IL9, Ctf2, Ifna4,
Ifna5, IL20, IL21, IL22, IL24 and IL31, remained undetected.
PDL thus creates an inflammatory microenvironment,
characterized by increased expression of STAT3-activating
cytokines among which IL6 is most prominent.
Cycling β-cells rarely activate STAT3. STAT3 supports cell
cycling of B-lymphocytes and several cancer cell types.35–37
Therefore, we examined expression of P-STAT3 in actively
cycling Ki67+ INS+ β-cells. At D7 and D14, respectively, 2.8-
and 2.5-fold more Ki67+ INS+ cells were observed in PDL as
compared with Sham tail (n= 3–6, Po0.005) (Figure 2a).
These data confirm our earlier reports21,34,38 and indicate
that, in PDL tail, both β-cell cycle and the number of β-cells
with activated STAT3 are increased. In line with our previous
observations, Ki67+ β-cells and P-STAT3+ β-cells were more
abundant in small islets of o20 β-cells as compared with
larger islets at D7 and D14 post PDL (Figure 2b,c). However,
no P-STAT3+Ki67+ β-cells were observed in PDL tail at D7 or
D14 (Figure 2d and Table 2). The close to zero probability to
find a P-STAT3+Ki67+ β-cell in PDL tail, as calculated by the
Wilson score confidence interval (95%) (Po0.001, Table 2),
indicates that the population of cycling β-cells does not
overlap with the population of β-cells with activated STAT3.
This phenomenon appears specific for β-cells, as P-STAT3+
Ki67+ duct- and α-cells were observed under the same
experimental conditions (Supplementary Figure S2c).
Conditional Stat3 knockout increases β-cell cycling in
PDL pancreas. The functional role of STAT3 in β-cells of PDL
pancreas was investigated in RIPCreERT;R26YFP;Stat3lox/lox
mice (Figure 3a) that received tamoxifen (TAM) at 5 weeks
of age, followed by a 14 days washout period. PDL was
performed at 8 weeks of age and analysis was carried out
2 weeks later. As the efficiency of recombination in β-cells was
high (89.9±1.11% of INS+ cells were YFP+) (Figure 3b),
RIPCreERT;R26YFP;Stat3lox/lox mice that received TAM are
hereafter referred to as Stat3−/−. Accordingly, an 85.8%
reduction in STAT3+ β-cells was observed in PDL tail of
Stat3−/− mice versus wild-type (WT) littermates (n=4)
(Figures 3c and d). Bodyweight, glycemia and glucose
tolerance (as determined by IPGTT) were similar in Stat3−/−
and WT, both before and after PDL (Supplementary Figures
S3a–c). The islet architecture in Stat3−/− mice appeared
normal (Figure 3e). In addition, the percentage of Ki67+
β-cells was similar in PDL heads of WT and Stat3−/− mice
(Figure 3f). The percentage of Ki67+ β-cells in PDL tail as
compared with PDL head was 4.5-fold higher In WT mice,
Table 1 Potential STAT3-activating cytokines and growth factors
Gene Assay ID
IL-6 family
IL-6 Mm.PT.53.10005566
IL-11 Mm.PT.53.9688576
IL-31 Mm.PT.53.30234305
Osm Mm.PT.53.10391002
LIF Mm.PT.5328778894
CNTF Mm.PT.5332700675.g
Ctf1 Mm.PT.53.5674019
Ctf2 Mm.PT.53.10088537
Clcf1 Mm.PT.53.10279842
IL-10 family
IL-10 Mm.PT.53.13531087
IL-19 Mm.PT.53.10424485
IL-20 Mm.PT.53.30487665
IL-22 Mm.PT.53.33202172
IL-24 Mm.PT.53.11689874
Interferons
IFNα4 Mm.PT.53.31028456.g
IFNα5 Mm.PT.53.32377263.g
IFNβ1 Mm.PT.53.29124254.g
IFNγ Mm.PT.53.13380517
Common γ-chain family
IL-2 Mm.PT.53.11478202
IL-7 Mm.PT.53.10325839
IL-9 Mm.PT.53.17016816
IL-15 Mm.PT.53.33007558.g
IL-21 Mm.PT.53.7853071
Growth Factors and hormones
Csf-1 Mm.PT.53a.32521769
Csf-2 Mm.PT.53a.30204640
Csf-3 Mm.PT.53.14133107.g
EGF Mm.PT.53.6246680
HGF Mm.PT.53.9088506
IGF-1 Mm.PT.53.32726889
VEGFα Mm.PT.53.31754187.g
PDGFβ Mm.PT.53a.32585335
Lep Mm.PT.53.13515402
IL-12 family
IL-27 Mm.PT.53.12354802
Inflammatory cytokines
IL-1β Mm.PT.53a.16901608
Tumor Necrosis Factor α (TNFα) Mm.PT.56a.12575861
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(n=4, Po0.05) and 5.7-fold in Stat3−/− mice (n=4,
Po0.005) (Figure 3f), indicating that STAT3 in β-cells is
dispensable for β-cell cycling after PDL. Notably, PDL-induced
β-cell cycle was amplified by 70% in the absence of STAT3
(Figure 3f). As Ki67+ β-cells are most prominent in small islets
of PDL tail in WT mice38,39 (Figure 2c), increased β-cell
cycling observed in Stat3−/− pancreas could conceivably
be caused by an increased amount of small islets. However,
the distribution of small, medium and large islets in Stat3−/−
mice was similar to that in the WT mice (Supple-
mentary Figure S4a). β-Cell cycling was only significantly
increased in large islets in Stat3−/− compared with WT mice.
(Figure 3g). Despite this increase, insulin content and β-cell
volume was similar in PDL tail of Stat3−/− and WT mice
(Figures 3h and i). The percentage of Ki67+ α-cells nor the
α- to β-cell ratio were altered in PDL tail of Stat3−/− compared
with WT mice (Supplementary Figures S4b and c).
STAT3 activation by rIL6 lowers β-cell cycling in PDL
pancreas. As IL6 is a potent activator of STAT3,40 recombi-
nant mouse IL6 (rIL6) was injected in the tail of D7 PDL
pancreas, in order to evaluate the effect of increased STAT3
activation on β-cell proliferation. As STAT3 protein has a short
half-life,41 pancreas was collected 1 h after injection
(Figure 4a). β-Cells (95± 3%) contained P-STAT3 in rIL6-
injected PDL tail as compared with only 13±5% following
vehicle injection (Figures 4b and c). Twenty-four hours after
rIL6 injection, the percentage of P-STAT3+ β-cells in PDL tail
had returned to baseline (Figure 4d). However, at this time
point, the percentage of Ki67+ β-cells in rIL6-injected PDL tail
was significantly lower when compared with vehicle control
(Figure 4e). These data suggest that activation of STAT3 by
exogenous IL6 blunts PDL-induced β-cell cycling. To deter-
mine whether endogenous IL6 contributed to STAT3 activa-
tion in PDL tail, an IL6-neutralizing antibody was injected in
Figure 2 Ki67+ β-cells differ from P-STAT3+ β-cells in PDL pancreas. (a) β-Cells with active cell cycle (Ki67+) at D7 and D14 post surgery (mean±S.E.M., D7: n= 3, D14:
n= 4-6, ***Po0.001, ns: P40.05, PDL tail versus Sham tail or PDL head by two-way ANOVA). (b) Proliferating β-cells (Ki67+ INS+) and (c) β-cells with activated STAT3
(P-STAT3+ INS+) cells in small (≤ 20 INS+ cells) and large (420 INS+ cells) islets, at D7 and D14 post surgery (mean± S.E.M., D7: n= 3, D14: n= 4-6, **Po0.005,
***Po0.001, ns: P40.05, small versus large islets in PDL and Sham by unpaired two-tailed t-test). (d) Ki67 and P-STAT3 in β-cells in PDL pancreas. Ki67+ β-cells are P-STAT3−
(white arrows)
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PDL tail at D6 post surgery. Twenty-four hours after injection,
the percentage of P-STAT3+ β-cells in PDL tail was 50% lower
in anti-IL6-injected as compared with isotype-injected pan-
creas (Figure 4d), indicating that endogenous IL6 contributes
to STAT3 activation in β-cells. However, β-cell cycling was not
significantly increased in anti-IL6-injected PDL tail compared
with isotype-injected PDL tail (Figure 4e), suggesting that a
50% reduction in STAT3 activation in β-cells is not sufficient to
activate the β-cell cycle as compared with deletion of a
functional STAT3 in 90% of β-cells. Alternatively, a STAT3-
mediated delay to initiate β-cell cycling may have preceded
injection of anti-IL6 antibody.
STAT3 protects β-cells from DNA damage in PDL. As the
increased number of cycling β-cells observed in β-cell-
specific Stat3−/− mice was not accompanied by an increase
in pancreatic insulin content and β-cell volume (Figures 3h
and i), we hypothesized that β-cells may be experiencing
stress under these conditions. Indeed, the mRNA expression
of deleterious cytokines Il1b, Ifng and Tnfa42 were significantly
higher in PDL tail at D3, 7 and 14 following surgery, with the
most prominent induction at D7 (Figure 5a). Although β-cells
that expressed the apoptosis marker cleaved caspase 3 could
be identified in WT and Stat3−/− PDL tail, their percentage
was very low (o0.1% of INS+ cells) (Figure 5b). In PDL tail of
Stat3−/− mice, the increase in percentage of cleaved caspase
3+ β-cells, as compared with WT, was not statistically
significant (Figure 5b). However, as late-apoptotic cells are
likely to be cleared quickly, we measured levels of the
β-cell death marker miR375 via quantitative reverse tran-
scription PCR in plasma of WT and Stat3−/− mice at
D1–D14 post PDL surgery. MiR375 is a β-cell-specific
microRNA and is discharged in the circulation at levels that
are proportionate to the number of necrotic or apoptotic
β-cells.43,44 Although miR375 could be detected at all time
points following PDL, its level at D1 was highest in Stat3−/−
compared with WT mice. These data suggest elevated β-cell
loss in PDL pancreas of Stat3−/− mice (Figure 5c). To assess
DNA damage in β-cells in PDL pancreas of Stat3−/− and WT
mice, expression of histone γ-H2AX (gH2AX) was investi-
gated. Phosphorylation of gH2AX at sites of DNA double-
strand breaks aids recruitment of DNA repair factors45 and is
typified by focal nuclear staining for gH2AX. In contrast,
homogenous or pan-nuclear staining for gH2ax is observed
in nuclei of cells with single-strand breaks induced by UV
irradiation, during nucleotide excision repair, in DNA frag-
mentation during apoptosis46 but also in nuclei of replicating
cells with undamaged DNA.47–49 In WT and Stat3−/− PDL,
immunostaining for gH2AX revealed β-cells whose nuclei
either displayed 1 or 2 positive nuclear foci (yellow arrow-
heads in Figure 5d) and Ki67+ β-cells whose nuclei displayed
homogenous positive nuclear gH2AX staining (white arrow in
Figure 5d). Homogenous staining for gH2AX was found in
approximately half of Ki67+ β-cells in PDL tail (51% in
Stat3−/− and 47% in WT mice) (Figure 5f). When these cells
were excluded from our DNA damage analysis, γ-H2AX+
Ki67− β-cells were 2.7-fold more abundant in PDL tail of
Stat3−/− versus WT mice (Figures 5e and f). The high
efficiency of Stat3 deletion (90%) in Stat3−/− mice appeared
crucial for the effect on DNA damage, as 50% inhibition of
STAT3 activity by injection of anti-IL6 antibody into PDL
pancreas did not affect the percentage of gH2AX+ Ki67−
β-cells (Figure 5g). Conversely, injection of IL6 in order to
increase STAT3 activation and diminish DNA damage in PDL
pancreas did not significantly affect the percentage of
gH2AX+ Ki67− β-cells compared with vehicle-injected PDL.
These findings suggest that the protective effect of STAT3 on
β-cell DNA integrity may not only depend on IL6-induced
activation of STAT3.
Discussion
STAT3 signaling is dispensable for normal pancreas
development but is involved in malignant processes such
as acinar-to-ductal metaplasia50 and pancreatic ductal
adenocarcinoma.36,51 PDL induces severe injury resulting in
massive loss of exocrine acinar cells and acinar-to-ductal
metaplasia, accompanied by local inflammation with infiltra-
tion of CD45+ cells and expression of various cytokines and
growth factors.21,23–25 We previously demonstrated that PDL
causes β-cell mass expansion, in part attributed to proliferation
of both pre-existing and newly formed β-cells.21,38 In the
present study, we investigated STAT3 activation in PDL and its
role in increased β-cell proliferation.
Activation of STAT3 is induced by factors specific to the
PDL environment.21,23–25 We identified 20 STAT3-activating
factors that are moderately or highly upregulated in ligated
pancreas, and that promote Stat3 gene expression and
protein activation specifically in β-cells located in small islets.
This preferential localization suggests involvement of STAT3
Table 2 P-STAT3+ proliferating β-cells in PDL and Sham pancreas
P-STAT3+ proliferating β-cells in PDL and Sham pancreas at 7 and 14 days post surgery
INS+ KI67+INS+ P-STAT+INS+ P-STAT3+KI67+INS+ [CI] %KI67+ %P-STAT3+
D7 D14 D7 D14 D7 D14 D7 D14 D7 D14 D7 D14
PDL tail 3786 4843 103 123 230 304 (0, 0.00051) (0, 0.00040) 2.72 2.54 6.08 6.28
PDL head 3130 3410 16 21 14 22 (0, 0.00061) (0, 0.00056) 0.51 0.62 0.45 0.65
SHAM tail 3167 4928 55 48 19 50 (0, 0.00061) (0, 0.00039) 1.74 0.97 0.6 1.01
Quantification of Ki67+ P-STAT3+ double-positive β-cells in PDL tail and head, and Sham tail at 7 and 14 days post surgery. INS+, number of β-cells quantified;
Ki67+INS+, number of proliferating β-cells quantified; P-STAT3+INS+, number of P-STAT3-positive β-cells; P-STAT3+Ki67+INS+ [CI], number of P-STAT3-positive and
Ki67-positive (proliferating) β-cells and the computed Wilson confidence interval, n= 3
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signaling in β-cell proliferation, as the latter is predominantly
observed within small islets. In addition, transduction of
cultured rat β-cells with a constitutively active form of STAT3
has been shown to induce a 2.8-fold higher BrdU incorporation
rate.52 Nevertheless, P-STAT3 and Ki67 did not co-localize in
β-cells of PDL pancreas, irrespective of islet size, whereas
STAT3 modulates β-cell cycling
S De Groef et al
6
Cell Death and Disease
co-localization of Ki67 and P-STAT3 was observed in α- and
duct cells, suggesting a direct role for STAT3 in the cell cycle of
these latter cell types only.
To address STAT3 function in β-cells, we generated mice
that allow efficient, inducible and β-cell-specific Stat3
knockout. These mice displayed normal bodyweight and
glycemic control, irrespective of PDL. This is in contrast to
RIPCre-induced deletion of Stat3 in developing β-cells and in
insulin-expressing hypothalamic neurons – where it disrupts
leptin signaling – which results in appetite gain and mild
obesity.15,16 Together with the fact that Cre expression per se
disturbs β-cell function,53 these off-target effects explain
why RIPCre;Stat3lox/lox mice become obese and glucose
intolerant.15,16 Our data suggest that, within the time frame
of our study, that is, 4–5 weeks after recombination, deletion of
Stat3 from adult β-cells or hypothalamic neurons (as shown by
yellow fluorescent protein (YFP) expression by hypothalamic
neurons; Supplementary Figure S5) does not interfere with
normal physiology and glucose handling. We therefore
assume that the effects of STAT3 inactivation in our model
are β-cell specific rather than systemic.
As Stat3-depleted β-cells still express Ki67 in PDL
pancreas, STAT3 signaling seems not to be required for
β-cell cycling. On the contrary, Stat3 deletion from β-cells
increased the percentage of Ki67+ β-cells in PDL pancreas.
Consequently, STAT3 appears to inhibit or at least delay the
Figure 3 β-Cell-specific Stat3 knockout stimulates β-cell cycling after PDL. (a) Schematic illustration of the inducible transgenic mouse model, RIP (rat insulin gene
promotor), CreERT (causes recombination fused to TAM-inducible estrogen receptor), R26 (Rosa26 promotor), loxP (locus of crossing over P1), STOP (transcriptional STOP
sequence), YFP, TAM. (b) Recombination efficiency as shown by immunostaining for YFP in INS+ cells in PDL tail of RipCreERTR26YFP mouse. (c) Immunostaining for STAT3 in
PDL tail from WT versus Stat3−/− mice, quantified in (d) as the percentage of STAT3+ INS+ cells in PDL tail from WTand Stat3−/− mice. (e) Cycling β-cells (Ki67+ INS+) were
observed in the islets of Stat3−/−mice that appeared normal based on the distribution of β- and α-cells (GCG+). (f) β-Cell cycling (Ki67+ INS+) in PDL head and tail pancreas from
WT and Stat3−/− mice at D14 post surgery. (g) Percentage INS+ cells that express Ki67+, in small (≤ 20 INS+ cells) and large (420 INS+ cells) islets of PDL head and tail
pancreas from WTand Stat3−/−mice at D14 post surgery. (h) Total insulin content (μg insulin per mg tissue) in PDL head and tail pancreas from WTand Stat3−/−mice. (i) β-Cell
volume (μl) in PDL tail pancreas fromWTand Stat3−/−mice. (d and f–i)mean± S.E.M., in (d and f–h) n= 4, in (i) n= 3–4, *Po0.05, **Po0.005, ***Po0.001, #Po0.0001, ns:
P40.05, WT versus Stat3−/− by unpaired two-tailed t-test
Figure 4 Recombinant IL6 stimulates STAT3 activation and blunts β-cell cycling in PDL pancreas. (a) Left: short-term effect of recombinant (r) IL6, injected at D7 post surgery
into PDL pancreas that was collected 1 h post injection. Right: long-term effect of recombinant (r) IL6 injected at D6 post surgery into PDL pancreas that was collected 24 h post
injection. (b) Immunostaining for P-STAT3 and insulin (INS) in PDL tail pancreas 1 h after (r)IL6 or vehicle injection at D7 post PDL. (c) Percentage of P-STAT3+ β-cells in PDL tail
1 h after vehicle or (r)IL6 injection (mean± S.E.M., n= 4, ***Po0.001, vehicle versus (r)IL6-injected PDL tail pancreas, by unpaired two-tailed t-test). (d) Percentage P-STAT3+
β-cells 24 h after vehicle, (r)IL6, isotype or anti-IL6 injection in PDL tail at D7 post PDL (n= 4, **Po0.005, ns: P40.05, vehicle versus (r)IL6-injected PDL tail pancreas and
isotype versus anti-IL6-injected PDL pancreas, two-way ANOVA). (e) Cycling β-cells (Ki67+ INS+) in PDL tail injected with vehicle, (r)IL6, isotope or anti-IL6 at D7 post surgery
(mean±S.E.M., n= 4, *Po0.05, ns: P40.05, vehicle versus (r)IL6-injected PDL tail pancreas and isotype versus anti-IL6-injected PDL pancreas, two-way ANOVA)
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initiation of the β-cell cycle in injured pancreas. In-depth
analysis of STAT3 activation dynamics and activation of the
β-cell cycle is required to define this inhibition or delay and its
effects. A similar role for STAT3 in growth arrest has
been identified in monocytes.40 In addition, in T-lymphocytes,
STAT3 inhibits the proliferative response to IL-2,54 whereas
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IL6-mediated activation of STAT3 inhibits hepatocyte prolife-
ration55 and growth of carcinoma and myeloid leukemia
cells.40 As the percentage of Ki67+ β-cells did not increase
in PDL head of pancreas in Stat3−/−mice, cytokines or growth
factors produced locally in PDL tail may signal via STAT3 and
prevent excessive β-cell proliferation specifically in PDL tail.
As a higher number of β-cells in small islets, a hotspot for β-cell
proliferation after PDL, displayed STAT3 activation, we
assume that STAT3 limits or delays excessive β-cell cycling
in pro-proliferative environments. Stat3 deletion allowed
increased β-cell proliferation, mainly in large islets. Possibly,
activation of β-cell division in Stat3−/− mice was less
pronounced in small islets, because this location already is a
privileged site for β-cell division. It is also a site where new
STAT3-competent β-cells are formed by differentiation, thus
escaping Stat3 deletion that was induced in pre-existing
β-cells before surgery.38
Increased β-cell cycling without an associated increase in
insulin content and β-cell volume in PDL pancreas of Stat3−/−
mice suggests that not all actively cycling β-cells complete
their cell cycle. However, the percentage Ki67+ β-cells that
contain the G2-Mmarker phosphohistone H3 was 30% in both
Stat3−/− and WT mice (data not shown). By consequence,
increased β-cell death in PDL pancreas of Stat3−/−mice is an
alternative explanation for increased β-cell cycling without a
concomitant increase in β-cell volume. An increase in β-cell
death was demonstrated by analysis of plasmamiR-375 levels
early after PDL in Stat3−/− mice.
Exposure to the pro-inflammatory cytokines IL1b and IFNg
that both are present in PDL pancreas, causes nitric oxide-
mediated DNA damage in β-cells that contain reduced
amounts of insulin and display suppressed glucose-
stimulated insulin secretion.56,57 The cytokine-induced DNA
damage that is characterized by an increased number of
β-cells with phosphorylated gH2AX leads to β-cell death.58
The percentage of β-cells expressing gH2AX was significantly
increased in mice with β-cell-specific Stat3−/−. Therefore,
STAT3 may serve as (part of) a mechanism to secure DNA
integrity before cell cycling. In regenerating liver, STAT3 lowers
hepatocyte cycling by increased expression of p21Cip1,55
coinciding with the upregulation of several DNA repair
enzymes.59 Mice that undergo PDL harbor increased levels
of inflammatory cytokines in the PDL tail, while displaying
normal glycemic control and only low numbers of apoptotic
(cleaved caspase3+) β-cells, indicative for a very tight
regulation and protection of β-cells from these deleterious
factors. Protection from cytokine-induced β-cell apoptosis has
been described for CNTF and humanin, signaling through
STAT3.60,61 We hypothesize the existence of a similar
protective role for STAT3 against inflammatory cytokines
in PDL.
To further support our observations in Stat3 knockout mice,
we injected recombinant IL6 into the ligated part of the
pancreas, thereby efficiently boosting local STAT3 signaling in
β-cells, as acinar atrophy and shrinkage of the tissue allows for
easy diffusion of the cytokines. Increased activation of STAT3
was sufficient to blunt PDL-induced activation of β-cell cycling,
similar to regenerating liver.55 DNA damage, however, did not
decrease on IL6 injection, likely because basal DNA damage
in β-cells is as low as 1.6% in G0 β-cells of PDL pancreas. In
addition, IL6-activated STAT3 can be negatively regulated by
SOCS3 that inhibits JAK activation by binding to gp130
through its SH2 domain. β-Cell-specific Socs3 knockout
maintains STAT3 activation and, consequently, the expression
of Bcl-xL that reduces streptozotocin-induced toxicity and
apoptosis.62 In PDL pancreas, STAT3 activation may be short
term and its signaling may be inhibited through negative
feedback by SOCS3.60 The abundance of STAT3 appears
crucial, as a 50% reduction by anti-IL6 injection was
insufficient to increase β-cell cycling or DNA damage in PDL
pancreas, as compared with the 90% reduction in Stat3−/−
mice. Factors other than IL6 may thus contribute to the control
of STAT3 activity in β-cells in ligated pancreas. Other potential
STAT3-activating factors that are increased in PDL pancreas
and for which receptors are expressed by β-cells include
CNTF,60 Leptin,63 IL10,64 HGF,65 IGF66 and PDGF.67 Although
these factors potentially modulate STAT3 in β-cells in PDL
pancreas, still many other cytokines and signaling pathways
may participate in the regulation of β-cell proliferation and
survival in PDL. Therefore, PDL offers an interesting tool for
the identification of signaling pathways and factors that
influence β-cell survival and growth in an inflammatory
environment.
In conclusion, our data indicate that STAT3 protects β-cells
from excessive cell cycling and from deleterious effects
exerted by cytokines that are inherent to the inflammatory
environment of duct-ligated pancreas.
Materials and Methods
Animals. All experiments were performed in accordance with the guidelines of
the ethical committee of the Vrije Universiteit Brussel. Mice were housed in micro-
isolator cages, maintained on a 12/12 h light–dark cycle and fed a standard
rodent diet.
Mouse manipulation. PDL was performed as described21,68 on 8- to 9-week-
old male mice. For IL6 and anti-IL6 intrapancreas injection, 8-week-old BALB/cJRj
Figure 5 STAT3 protects β-cells from DNA damage in PDL pancreas. (a) Abundance of mRNA encoding inflammatory cytokines (Ifng, Tnfa and Il1b) in PDL tail. Data are
expressed as fold change compared with transcript level in Sham tail (1) (D3: n= 4, D7: n= 4, D14: n= 3, *Po0.05, **Po0.005, ***Po0.001, #Po0.0001, ns: P40.05, Sham
tail versus PDL tail by unpaired two-tailed t-test). (b) Percentage β-cell apoptosis (cCASP3+ INS+) in PDL head and tail pancreas from WTand Stat3−/− mice at D14 post surgery
(n= 4, *Po0.05, ns: P40.05, WT versus Stat3−/−, two way ANOVA). (c) Abundance of miR375 in plasma fromWTand Stat3−/−mice at D1, D3, D5, D7, D10 and D14 post PDL
surgery and in plasma of positive control for β-cell death 24 h after Alloxan injection (ALX). Data are expressed as Ct values. WT, n= 5; Stat3−/−, n= 4; *Po0.05, ns: P40.05,
WT versus Stat3−/− by unpaired two-tailed t-test) (d) Immunostaining for Ki67 and gH2AX in PDL tail pancreas from Stat3−/−mice showing two forms of gH2AX nuclear staining:
homogenous nuclear labeling in proliferating β-cells (white arrows) and nuclear foci (yellow arrows). (e) gH2AX in PDL tail from WT and Stat3−/− mice at D14 post surgery.
(f) Percentage non-cycling β-cells with DNA damage (gH2AX+ Ki67− INS+) in PDL tail from WTand Stat3−/−mice at D14 post surgery (n= 4, *Po0.05, ns: P40.05, WT versus
Stat3−/−, by unpaired two-tailed t-test). (g) Percentage non-cycling β-cells with DNA damage (gH2AX+ Ki67− INS+) in PDL tail pancreas injected with vehicle, (r)IL6, isotype or
anti-IL6 at D7 post surgery (n= 4, *Po0.05, ns: P40.05, two-way ANOVA)
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male mice (Janvier, Saint Berthevin, France) were anesthetized by i.p. injection of
3.5 mg ketamine+0.5 mg xylazine per kg bodyweight. The ligated pancreas was
exposed through a lateral incision and injected with either 30 μl of 0.1 mg/ml carrier-
free rIL6 (R&D Systems, Minneapolis, MN, USA), vehicle (0.9% NaCl), 0.1 or
0.05 mg/ml anti-IL6 (clone MP520F3, Hycult Biotech, Uden, The Netherlands) or rat
IgG (Vector Laboratories, Burlingame, CA, USA). TAM (Sigma-Aldrich, St. Louis,
MO, USA) was prepared and administered as described.38
β-Cell-specific Stat3 knockout mice. β-Cell-specific Stat3 knockout mice
were generated by crossing RIPCreER;R26YFP mice with Stat3lox/lox mice. RIPCreER;
R26YFP mice express a fusion protein of Cre recombinase and a mutated TAM
responsive estrogen receptor under control of the rat insulin promoter (RIP) in
addition to conditional YFP reporter expression under control of the Rosa26
promotor (R26).69 In Stat3lox/lox mice, exon 16–21 encoding the SH-domain of the
STAT3 protein is flanked by loxP sites. As control mice, CreER-deficient Stat3lox/lox
littermates were used. Genotyping was performed on tail snips using primers for Cre
(forward 5′-CCTGTTTTGCACGTTCACCG-3′, reverse 5′-ATGCTTCTGTCCGTTT
GCCG-3′), YFP (forward 5′-AAAGTCGCTCTGAGTTGTTA-3′, reverse 5′-GGAGC
GGGAGAAATGGATATG-3′), splice acceptor (5′-CATCAAGGAAACCCTGGACTACT
-3′) and for the Stat3 floxed allele (forward 5′-ATTGGAACCTGGGACCAAGTG-3′,
reverse 5′-ACATGTACTTACAGGGTGTGT-3′). RIPCreERT;R26YFP; Stat3lox/lox mice
or WT RIPCreERT negative littermates received 4 mg TAM, repeated once every
other day, for five injections in total, followed by a 14-day washout period and PDL
surgery. PDL head and PDL tail was collected 14 days post surgery.
Metabolic follow-up. Mice were fasted for 2 h before measurement of
glycemia. For IPGTT, mice were fasted for 16 h before i.p. injection with glucose
(2 g per kg body weight). Blood glucose concentration was measured from tail vein
blood with a portable glucometer (Glucomen Lx Plus, Menarini, Florence, Italy).
Total pancreas insulin content was determined using a mouse insulin radio-
immunoassay kit (Linco Research, St. Charles, MO, USA).
RNA analysis. PDL and Sham tissues were dissociated to single cells using
collagenase (0.8 mg/ml, Sigma-Aldrich) and trypsin (1 mg/ml, Sigma-Aldrich),
passed through a 66-μm filter and resuspended in isolation medium (Lonza, Basel,
Switzerland). β-Cells were isolated by sorting on a FACSDiva 6.0 (Becton
Dickinson, Franklin Lakes, NJ, USA) RFP+ cells from PDL’ed MIPmRFP mice followed
by a second round of sorting using Zn2+ chelator 6-methoxy-8-p-toluenesulfona-
mido-quinolone (Thermo Fisher Scientific, Waltham, MA, USA) as β-cell probe.
Total RNA was isolated from cells (RNeasy, Qiagen, Venlo, The Netherlands) or
tissue (TRIzol, Thermo Fisher). RNA analysis of cells or tissue was as described,38
using primers listed in Supplementary Table S1.
Protein analysis. Samples for immunostaining were fixed overnight at 4 °C in
10% neutral buffered formalin, embedded in paraffin and sectioned at 5 μm.
Primary antibodies used were guinea pig polyclonal anti-insulin and rabbit
polyclonal anti-glucagon (Diabetes Research Center, Vrije Universiteit Brussel,
Brussels, Belgium), rabbit polyclonal anti-Ki67 (eBioscience, San Diego, CA, USA),
rat polyclonal anti KRT19 (Developmental Studies Hybridoma Bank, University of
Iowa, Iowa City, IA, USA), rabbit monoclonal anti-phosphoSTAT3 (P-STAT3)
(phospho Y705) and anti-γ H2AX (gH2AX) (phospho S139), goat polyclonal anti-
GFP, rabbit polyclonal anti-cleaved caspase3 (Asp175) (all from Abcam, Cambridge,
UK) and mouse monoclonal anti-STAT3 (Cell Signaling Technology, Danvers, MA,
USA), Staining for GFP, KRT19, glucagon, P-STAT3, STAT3 and gH2AX required
heat-mediated antigen retrieval with 10 mM citrate pH 6.0. Cyanine- and AlexaFluor-
labeled secondary antibodies were from Jackson ImmunoResearch, Newmarket,
UK. Nuclei were stained with Hoechst 33342. Images were acquired with a BX-UCB
fluorescence microscope (Olympus, Tokyo, Japan) equipped with an Orca r2
camera (Hamamatsu Photonics, Hamamatsu, Japan). Images were analyzed with
SmartCapture 3 (Digital Scientific UK, Cambridge, UK). β-Cell proliferation, STAT3
activation, β-cell apoptosis and DNA damage in β-cells were analyzed by
determining the proportion of insulin-positive cells co-expressing Ki67, phospho-
STAT3, cleaved caspase-3 or gH2AX, respectively. At least 2000 β-cells were
quantified per sample. Quantification was done by manual counting using the cell
counter plugin and SmartCaptureLite plugin (Digital Scientific UK) in ImageJ (NIH,
Bethesda, MA, USA). The total β-cell volume was analyzed as previously
described.21,38,70 Images were captured with an inverted microscope (Nikon
Instruments, Amstelveen, The Netherlands) equipped with a Hamamatsu digital
camera c10600 (Olympus) or with a multiphoton microscope (LSM710 NLO with a
TiSa laser, Zeiss, Thornwood, NY, USA) and analysed using Smartcapture 3
(version 3.0.8) NIS AR2.30 Imaging Software (Nikon France, Champigny-sur-Marne,
France) or Improvision Volocity LE (version 5.0) (PerkinElmer, Waltham, MA, USA)
and ImageJ software (https://imagej.nih.gov/ij/).71
miR375 analysis in plasma. Plasma was obtained from tail vein blood from
adult WT and Stat3−/− mice at D1, D3, D5, D7, D10 and D14 post PDL surgery.
Analysis of miR375 was performed as described by Roels et al.72 (In preparation).
Statistical analysis. Data were analyzed using GraphPad Prism 5 (GraphPad
Software, San Diego, CA, USA) and are expressed as mean±S.E.M. of at least
three independent experiments. Data were analyzed by unpaired two-tailed
Student’s t-test or with one-way or two-way ANOVA with Bonferroni post-hoc test
and were considered statistically significant when Po0.05. To determine the
confidence interval for the proportion of P-STAT3+ Ki67+ β-cells, the Wilson score
confidence interval was used. Wilson scores have coverage probabilities close to
the nominal confidence level, also for small samples sizes or extreme frequencies
close to zero.
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